Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis

por Graves, Jennifer, Galetta, Steven L, Palmer, Jeffrey, Margolin, David H, Rizzo, Marco, Bilbruck, John, Balcer, Laura J
Publicado 2013

Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis

por Arroyo, Rafael, Bury, Denise P, Guo, Jennifer D, Margolin, David H, Melanson, Maria, Daizadeh, Nadia, Cella, David
Publicado 2019

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis

por Phelps, Richard, Winston, Jonathan A, Wynn, Daniel, Habek, Mario, Hartung, Hans-Peter, Havrdová, Eva Kubala, Markowitz, Glen S, Margolin, David H, Rodriguez, Claudio E, Baker, Darren P, Coles, Alasdair J
Publicado 2019

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

por Giovannoni, Gavin, Cohen, Jeffrey A., Coles, Alasdair J., Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Margolin, David H., Lake, Stephen L., Kaup, Susan M., Panzara, Michael A., Compston, D. Alastair S.
Publicado 2016

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

por Horáková, Dana, Boster, Aaron, Bertolotto, Antonio, Freedman, Mark S, Firmino*, Isabel, Cavalier, Steven J, Jacobs*, Alan K, Thangavelu*, Karthinathan, Daizadeh, Nadia, Poole*, Elizabeth M, Baker, Darren P, Margolin*, David H, Ziemssen, Tjalf
Publicado 2020

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

por Wray, Sibyl, Havrdova, Eva, Snydman, David R, Arnold, Douglas L, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Selmaj, Krzysztof W, Weiner, Howard L, Daizadeh, Nadia, Margolin, David H, Chirieac, Madalina C, Compston, D Alastair S
Publicado 2018

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

por Van Wijmeersch, Bart, Singer, Barry A, Boster, Aaron, Broadley, Simon, Fernández, Óscar, Freedman, Mark S, Izquierdo, Guillermo, Lycke, Jan, Pozzilli, Carlo, Sharrack, Basil, Steingo, Brian, Wiendl, Heinz, Wray, Sibyl, Ziemssen, Tjalf, Chung, Luke, Margolin, David H, Thangavelu, Karthinathan, Vermersch, Patrick
Publicado 2019

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

por Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.
Publicado 2021

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

por Arnold, Douglas L., Fisher, Elizabeth, Brinar, Vesna V., Cohen, Jeffrey A., Coles, Alasdair J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Stojanovic, Miroslav, Weiner, Howard L., Lake, Stephen L., Margolin, David H., Thomas, David R., Panzara, Michael A., Compston, D. Alastair S.
Publicado 2016

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

por Cuker, Adam, Bass, Ann D, Nadj, Congor, Agius, Mark A, Steingo, Brian, Selmaj, Krzysztof W, Thoits, Timothy, Guerreiro, Alexandre, Van Wijmeersch, Bart, Ziemssen, Tjalf, Meuth, Sven G, LaGanke, Christopher C, Thangavelu, Karthinathan, Rodriguez, Claudio E, Baker, Darren P, Margolin, David H, Jannsens, Ann
Publicado 2019

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

por Dayan, Colin M., Lecumberri, Beatriz, Muller, Ilaria, Ganesananthan, Sashiananthan, Hunter, Samuel F., Selmaj, Krzysztof W., Hartung, Hans-Peter, Havrdova, Eva K., LaGanke, Christopher C., Ziemssen, Tjalf, Van Wijmeersch, Bart, Meuth, Sven G., Margolin, David H., Poole, Elizabeth M., Baker, Darren P., Senior, Peter A.
Publicado 2023

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

por Coles, Alasdair J., Cohen, Jeffrey A., Fox, Edward J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Chirieac, Madalina C., Jody, Darlene, Xenopoulos, Panos, Hogan, Richard J., Panzara, Michael A., Arnold, Douglas L.
Publicado 2017

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

por Havrdova, Eva, Arnold, Douglas L., Cohen, Jeffrey A., Hartung, Hans-Peter, Fox, Edward J., Giovannoni, Gavin, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio E., Jody, Darlene, Hogan, Richard J., Xenopoulos, Panos, Panzara, Michael A., Coles, Alasdair J.
Publicado 2017